Literature DB >> 14985866

Comparison of peritoneal equilibration test with 99mTc-DTPA excretion in the assessment of peritoneal permeability.

B K Das1, M S Senthilnathan, P K Pradhan, S Nagabhushan, T K Jeloka, R K Sharma.   

Abstract

Assessment of peritoneal permeability is necessary for successful management of end-stage renal disease (ESRD) patients by continuous ambulatory peritoneal dialysis (CAPD). The objective of this study was to develop an alternative method of assessing the peritoneal permeability and to compare this method with the conventional method, the peritoneal equilibrium test, first described by Twardowski in 1987. Twenty patients undergoing regular CAPD were included in this study. Before starting the peritoneal dialysis, 370 MBq (10 mCi) technetium-99m diethylene triamine penta-acetic acid ((99m)Tc-DTPA) was injected intravenously. A standard dose of the same quantity was kept and used later for calculations. At the end of 4 h, a dialysate fluid sample (1 ml) was collected and the total dialysis effluent fluid volume was measured. Excretion of (99m)Tc-DTPA into the dialysate fluid as a percentage of the injected dose was calculated. Simultaneously, standard peritoneal equilibrium test values were recorded for comparison. Peritoneal excretion of (99m)Tc-DTPA ranged from 8% to 25% of the injected dose, depending on the peritoneal membrane permeability. When the results were compared with the conventional method, a good correlation (r=0.79) was found. This innovative radionuclide technique is a simple and convenient method to assess the peritoneal membrane permeability and can be used as an alternative to the peritoneal equilibrium test, which is very cumbersome and associated with many limitations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14985866     DOI: 10.1007/s00259-004-1467-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  8 in total

1.  Reproducibility of the peritoneal equilibration test in CAPD patients.

Authors:  H Trivedi; R Khanna; W K Lo; B F Prowant; K D Nolph
Journal:  ASAIO J       Date:  1994 Jul-Sep       Impact factor: 2.872

2.  Iodine-131 ablation therapy for a patient receiving peritoneal dialysis.

Authors:  M E Toubert; C Michel; F Metivier; M C Peker; J D Rain
Journal:  Clin Nucl Med       Date:  2001-04       Impact factor: 7.794

3.  Calculation of 6-hour D/P creatinine ratio from the 4-hour peritoneal equilibration test. The effect of dwell duration on the results.

Authors:  R Mehrotra; R Khanna; T C Yang; P Kathuria; H L Moore; B F Prowant; K D Nolph; Z J Twardowski
Journal:  Perit Dial Int       Date:  1997 May-Jun       Impact factor: 1.756

Review 4.  Clinical value of standardized equilibration tests in CAPD patients.

Authors:  Z J Twardowski
Journal:  Blood Purif       Date:  1989       Impact factor: 2.614

5.  The kinetics of ultrafiltration during peritoneal dialysis: the role of lymphatics.

Authors:  K D Nolph; R Mactier; R Khanna; Z J Twardowski; H Moore; T McGary
Journal:  Kidney Int       Date:  1987-08       Impact factor: 10.612

6.  Assessment of dialysis dose by measured clearance versus extrapolated data.

Authors:  J M Burkart; J R Jordan; M V Rocco
Journal:  Perit Dial Int       Date:  1993       Impact factor: 1.756

7.  Prospective controlled trial of a Y-connector and disinfectant to prevent peritonitis in continuous ambulatory peritoneal dialysis.

Authors:  R Maiorca; A Cantaluppi; G C Cancarini; A Scalamogna; R Broccoli; G Graziani; S Brasa; C Ponticelli
Journal:  Lancet       Date:  1983-09-17       Impact factor: 79.321

8.  Continuous ambulatory peritoneal dialysis.

Authors:  R P Popovich; J W Moncrief; K D Nolph; A J Ghods; Z J Twardowski; W K Pyle
Journal:  Ann Intern Med       Date:  1978-04       Impact factor: 25.391

  8 in total
  1 in total

1.  Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model.

Authors:  J-P Delord; S Quideau; P Rochaix; O Caselles; B Couderc; I Hennebelle; F Courbon; P Canal; B C Allal
Journal:  Br J Cancer       Date:  2010-06-01       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.